NeuroMetrix

NeuroMetrix is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company currently markets products for the detection, diagnosis, and monitoring of diabetic neuropathies such as diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome).

NURO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NeuroMetrix, Inc. Is Fair to Shareholders

Transforming neurological care with innovation

Neurostimulation Tech

Companies that offer solutions for pain management, neuropathies, and related disorders and migraines.

Companies that provide solutions for Parkinson's disease, epilepsy, and speech and movement disorders.

Companies that offer treatments for depression, Alzheimer's, and other mental health-related disorders.

Companies that offer solutions for heart-related medical issues such as acute decompensated heart failure and high blood pressure.

Companies that offer solutions for urinary or fecal incontinence, autoimmune diseases and other functional impairments

Companies that offer solutions for hearing or vision impairment, sleep-related conditions, and other disorders, including obesity treatments.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

ANALYST_QUICK_TAKE

INCUMBENTS_PRESENT

<div>
 ElectroCore, a bioelectronic firm, has decided to buy neurotechnology device company NeuroMetrix. The deal involves the equivalent amount of NeuroMetrix's net cash balance at closing, with contingent value rights worth up to USD 0.5 million in royalties. The acquisition is expected to complete by the end of Q1 2025, pending NeuroMetrix shareholder approval and other standard conditions.
 With this purchase, electroCore plans to broaden its range of non-invasive therapies and make use of its existing distribution channels, specifically the VA Hospital System. The aim is to speed up the acceptance of NeuroMetrix’s Quell solution.&nbsp;
 NeuroMetrix specializes in creating neurotechnology devices for chronic pain and diabetes care. Its primary product, Quell, is a wearable, app, and cloud-based neuromodulation system for managing fibromyalgia symptoms and lower-extremity chronic pain. Additionally, the company has DPNCheck, a test for peripheral neuropathy screening, which will be sold off before the acquisition is finalized.
 
</div> Analyst QuickTake: 
 M&amp;A in the DTx space has been active for the past year. DTx company Sharecare was acquired by investment firm Altaris in <a href="https: 
//sp-edge.com/updates/30782"> June 2024 </a> . Sidekick Health acquired PINK! in <a href="https: 
//sp-edge.com/updates/30558"> June 2024 </a> and aidhere in <a href="https: 
//sp-edge.com/updates/22714"> October 2023 </a> to expand its offerings. Additionally, Click Therapeutics acquired Better Therapeutics' DTx assets in <a href="https: 
//sp-edge.com/updates/29686"> May 2024 </a> .

NeuroMetrix

Featured Industries

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless